ncRNA basic information
ncRNA ID:
MI0000681
ncRNA Database:
miRBase
ncRNA Name:
miR-155
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
NA
ncRNA Pathway:
Nrf2 signaling pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB01169 (APRD00171)
Drug Name:
Arsenic trioxide
Drug Method:
In this study, we identified a high level of expression of miR-155 in a human lung adenocarcinoma A549R cell line that is highly resistant to ATO. We showed that the high level of miR-155 was associated with increased levels of cell survival, colony formation, cell migration and decreased cellular apoptosis, and this was mediated by high levels of Nrf2, NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1) and a high ratio of Bcl-2/Bax. Overexpression of the miR-155 mimic in A549R cells resulted in increased levels of colony formation and cell migration as well as reduced apoptosis along with increased Nrf2, NQO1 and HO-1. In contrast, silencing of miR-155 expression with its inhibitor in the cells, significantly decreased the cellular levels of Nrf2, NQO1 and HO-1 as well as the ratio of Bcl-2/Bax. This subsequently reduced the level of colony formation and cell migration facilitating ATO-induced apoptosis. Our results indicate that miR-155 mediated ATO resistance by upregulating the Nrf2 signaling pathway, but downregulating cellular apoptosis in lung cancer cells.
Drug Response:
resistant
Cancer basic information
Cancer:
lung cancer
Tissue/Cell:
cell line ( A549,A549R )
Other information
Title:
miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells.
Journal:
Sci Rep
Published:
2017
PubMed ID:
28939896